Friday, 10 Oct 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    Fintech Forward 2025 Delivers with 38 Industry-Shaping Partnerships and Strategic Agreements Signed
    Fintech Forward 2025 Delivers with 38 Industry-Shaping Partnerships and Strategic Agreements Signed
    10/10/2025
    Kimberly-Clark Launches Enhanced Global Partnerships to Advance Essential Care for 24 Million Women and Girls
    Kimberly-Clark Launches Enhanced Global Partnerships to Advance Essential Care for 24 Million Women and Girls
    10/10/2025
    GEDU Group to Become Largest Foreign Education Investor in India
    GEDU Group to Become Largest Foreign Education Investor in India
    09/10/2025
    Signs of Change: Equipping Teachers with Tools for Inclusive Classrooms
    Signs of Change: Equipping Teachers with Tools for Inclusive Classrooms
    09/10/2025
    Nobel Prize 2025 in Medicine: Three Scientists Who Changed the Future of Immunology
    Nobel Prize 2025 in Medicine: Three Scientists Who Changed the Future of Immunology
    08/10/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • global
  • Business
  • june
  • announced
  • today
  •  and
  •  the
  • july
  • company
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

GlobeNews Wire
Last updated: 10/06/2025 1:52 AM
GlobeNews Wire
Share
5 Min Read
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions
SHARE
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes

June 09, 2025 16:05 ET  | Source: Sana Biotechnology, Inc

SEATTLE, June 09, 2025 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The presentation will be held during a joint American Diabetes Association (ADA)/International Pancreas & Islet Transplant Association (IPITA) symposium at the 85th Annual ADA Scientific Sessions taking place June 20-23, 2025 in Chicago, IL.

Presentation details:

Symposium Title:   Joint ADA/IPITA Symposium: Outpacing the Immune System—Sprinting Towards Immune Protection for Cell Replacement Therapy
Presentation Title:   Hypoimmune Pancreatic Islet Transplantation in Adult Subjects with Type 1 Diabetes
Presentation Date:   Monday, June 23, 2025
Presentation Time:   9:00 – 9:20 a.m. CT
Location:   W192 A-C
     

About Sana

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA and Bothell, WA.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the company’s vision and expectations regarding participation in and the presentation at the 85th Annual American Diabetes Association Scientific Sessions, including the content of such presentation. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market, and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s Securities and Exchange Commission reports, including but not limited to its Quarterly Report on Form 10-Q dated May 8, 2025. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com

Ascensia Launches Global Art Competition Exploring the Link Between Diabetes and Anxiety
GAC’s Feng Xingya: User-Centric Green Solutions for a Sustainable Future
Zero Trust Security Reduces Cyber Insurance Claims, Preventing up to $465 Billion Annually in Global Economic Loss from Cyber Attacks
Kia Tasman Blazes New Trail for Pickup Truck Segment with Exceptional OffRoad Ability
NEXEN TIRE Introduces CuttingEdge High Dynamic Driving Simulator to Accelerate Tire Development
TAGGED:Adventureannounced anassociationbiotechnologycellschangingclinicalcompanydatadiabetesengineeredfocusedglobehighlightingincinvestigatorsponsoredisletjunenasdaqnewswireongoingpatientspodiumpossiblepresentationsanaseattlesourcetodayupcoming
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

Beach Cities Commercial Bank Announces Leadership Changes
Business

Beach Cities Commercial Bank Announces Leadership Changes

12/07/2025
Altius Inspiro Wins 2025 Fortress Cybersecurity Award for Network Security
Tech

Altius Inspiro Wins 2025 Fortress Cybersecurity Award for Network Security

19/06/2025
Ben’s Original Reaffirms Its Mission to Provide Simple, Tasty Meals That Bring People Together Through New “Keep It Original” Global Brand Platform
Food

Ben’s Original Reaffirms Its Mission to Provide Simple, Tasty Meals That Bring People Together Through New “Keep It Original” Global Brand Platform

09/07/2025
CloudFirst to Join Performive in Strategic Growth Transaction
Tech

CloudFirst to Join Performive in Strategic Growth Transaction

16/07/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?